Psoriasis vulgaris is a human autoimmune disease that manifests as an inflammatory skin condition characterized by focal and coalescing cutaneous plaques with consistent scaling and variable erythema. Approximately 80% of patients affected with psoriasis have mild to moderate disease that can be treated with topical agents that are efficacious. However, the use of topical agents as monotherapy in the setting of extensive or recalcitrant disease is typically limited. Topical medications can sometimes be used concurrently to take advantage of varied mechanisms of action. In this study, an IMQ induced mouse model that recapitulates the phenotype of the clinical disease was utilized to determine the efficacy and safety of single and combined therapies.